NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02367781,A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT02367781,IMpower130,COMPLETED,"This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).",YES,"Carcinoma, Non-Squamous Non-Small Cell Lung","DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Carboplatin|DRUG: Nab-Paclitaxel|DRUG: Pemetrexed","Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population, PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first in the ITT-WT population., Up to approximately 35 months after first patient enrolled|Overall Survival (OS) in the ITT-WT Population, OS is defined as the time between the date of randomization and date of death from any cause in the ITT-WT population., Up to approximately 35 months after first patient enrolled","PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population, PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation., Up to approximately 35 months after first subject enrolled|OS as Determined by the Investigator Using Recist v1.1 in the ITT Population, OS is defined as the time between the date of randomization and date of death from any cause in the ITT population., Up to approximately 41 months after first subject enrolled|OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population, OS is defined as the time between the date of randomization and date of death from any cause in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation., Up to approximately 35 months after first patient enrolled|Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population, ORR (confirmation not required) is defined as the proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by the investigator in the ITT-WT population., Up to approximately 41 months after first subject enrolled|Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population, ORR (confirmation not required) is defined as proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by investigator in ITT population, PD-L1 Expression population, and PD-L1 Expression WT population. ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. PD-L1 expression WT population is defined as PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation., Up to approximately 35 months after first subject enrolled|Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population, DOR,defined for participants with objective response (OR) as time from 1st documented OR to documented disease progression as determined by investigator using RECIST v1.1,or death from any cause,whichever occurs 1st.ITT defined as all randomized participants,regardless of receipt of assigned treatment.ITT-WT defined as ITT population excluding participants with activating EGFR mutation or ALK translocation.PD-L1 expression population is defined as one of following:PD-L1 IHC TC1/2/3 or IC1/2/3 population,defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue;PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue;PD-L1 IHC TC3 or IC3 population,defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue.PD-L1 expression WT is defined as PD-L1 expression population excluding participants with activating EGFR mutation or ALK translocation., Up to approximately 35 months after first subject enrolled|Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population, The OS rate at the 1- and 2-year landmark time points after randomization., Up to 41 months after first patient enrolled, years 1 and 2 reported|Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population, The OS rate at the 1- and 2-year landmark time points after randomization in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation., Up to 35 months after first patient enrolled, years 1 and 2 reported|Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population, Defined as time from randomization to confirmed deterioration (10-point change) on the combined European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and supplemental lung cancer module (EORTC QLQ-LC13) symptom subscales., Up to approximately 35 months after first subject enrolled|Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale, Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \& 2, 'Cough' score is mean of question 3 \& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea \& cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant., Up to approximately 35 months after first subject enrolled|Percentage of Participants With Adverse Events, Percentage of participants with at least one adverse event. Adverse event onset date before cross over., Up to approximately 69 months after first patient enrolled|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab, Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B Carboplatin+nab-paclitaxel Crossover Participants, Up to approximately 35 months after first subject enrolled|Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm, Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes., Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)|Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel, Predose samples will be collected on the same day of treatment administration., Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days)|Plasma Concentrations of Carboplatin, Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 hour after carboplatin infusion (infusion duration=15 to 30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)|Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel, Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,723,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GO29537|2014-003206-32,2015-04-16,2018-03-15,2021-01-18,2015-02-20,2019-04-03,2021-08-09,"Highlands Oncology Group, Springdale, Arkansas, 72762, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, 94611, United States|Kaiser Permanente Medical Center - Roseville, Roseville, California, 95661, United States|Kaiser Permanente - Sacramento Medical Center and Medical Offices, Sacramento, California, 95825, United States|Kaiser Permanente - San Francisco Medical Center, San Francisco, California, 94118, United States|Kaiser Permanente - San Jose Medical Center, San Jose, California, 95119, United States|Kaiser Permanente - San Leandro Medical Center, San Leandro, California, 94577, United States|Kaiser Permanente - Santa Clara, Santa Clara, California, 95051, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, 94080, United States|Kaiser Permanente; Oncology Clinical Trials, Vallejo, California, 94589, United States|Kaiser Permanente - Walnut Creek, Walnut Creek, California, 94596, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, 85234, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, 06360, United States|University of Miami School of Medicine - Sylvester at Deerfield, Deerfield Beach, Florida, Suite 200, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, 33916, United States|Florida Hospital, Orlando, Florida, 32803, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, 33705, United States|SCRI Florida Cancer Specialists East, West Palm Beach, Florida, 33401, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, 30607, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Carrollton, Georgia, 30117, United States|Suburban Hematology / Oncology Associates, Lawrenceville, Georgia, 30046, United States|Southeastern Regional Medical Center, Inc., Newnan, Georgia, 30265, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois, 60435, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Quincy Medical Group, Quincy, Illinois, 62301, United States|Southern Illinois University, Simmons Cancer Institute, Springfield, Illinois, 62794, United States|Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, 46845, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242-1083, United States|Lahey Clinic Med Ctr, Lexington, Kentucky, 02421, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, 20814, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Southcoast Health System, Fairhaven, Massachusetts, 02719, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Hematology and Oncology Associates at Bridgepoint, Tupelo, Mississippi, 38801, United States|Southeast Nebraska Cancer Ctr, Lincoln, Nebraska, 68510, United States|Va Sierra Nevada Health Care System, Reno, Nevada, 89502, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, 07631, United States|Saint Barnabas Medical Center, Livingston, New Jersey, 07039, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, 08901, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, 10016, United States|Clinical Research Alliance, Westbury, New York, 11590, United States|Presbyterian Hospital, Charlotte, North Carolina, 28204, United States|Duke University Medical Center; Department of Medicine, Durham, North Carolina, 27710, United States|W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, 45219, United States|Mark H. Zangmeister Center, Columbus, Ohio, 43219, United States|Oncology Hematology Care, Inc., Hamilton, Ohio, 45103, United States|Pinnacle Health, Harrisburg, Pennsylvania, 17110, United States|Lancaster General Hospital, Lancaster, Pennsylvania, 17604, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Greenville Health System; Cancer Center, Greenville, South Carolina, 29605-4292, United States|University Oncology Associates, Chattanooga, Tennessee, 37403, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, 37404, United States|SCRI The Center For Cancer and Blood Disorders, Denton, Texas, 76210, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Cancer Care Network of South Texas - SAT & BC, San Antonio, Texas, 78217, United States|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|CHU Ambroise Paré, Mons, 7000, Belgium|Werken Glorieux VZW, Ronse, 9600, Belgium|GasthuisZusters Antwerpen, Wilrijk, 2610, Belgium|BC Cancer - Surrey, Surrey, British Columbia, V3V 1Z2, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, L4M 6M2, Canada|William Osler Health Centre, Etobicoke, Ontario, M9V 1R8, Canada|Cite de La Sante de Laval; Hemato-Oncologie, Laval, Quebec, H7M 3L9, Canada|Hôpital Maisonneuve - Rosemont, Montreal, Quebec, H1T 2M4, Canada|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, 33300, France|Institut Hospitalier Franco-Britannique; Cancerologie, Levallois-Perret, 92300, France|Fondation Hopital Saint Joseph;Cardiologie Clinique, Marseille, 13285, France|Clinique Clementville; Hopital De Jour, Montpellier, 34070, France|Centre D'oncologie de Gentilly; Service Oncologie Medicale, Nancy, 54100, France|Clinique Catherine de Sienne, Nantes, 44202, France|Hopital American de Paris (American Hospital of Paris), Neuilly sur Seine, 92200, France|HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune, Orleans, 45100, France|Hopital Pontchaillou, Rennes, 35033, France|Centre Hospitalier Regional Sud Reunion; Service de Pneumologie, Saint Pierre, 97448, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, 94160, France|CHRU Nancy; Pneumologie, Vandoeuvre-lès-nancy, 54511, France|Charite - Universitätsmedizin Berlin; Klinik fur Infektiologie und Pneumologie, Berlin, 13353, Germany|Klinikum Chemnitz gGmbH, Chemnitz, 09116, Germany|Bezirksklinikum Obermain, Ebensfeld, 96250, Germany|Helios Klinikum Erfurt, Erfurt, 99089, Germany|St. Antonius Hospital, Eschweiler, 52249, Germany|Klinikum Esslingen GmbH; Frauenklinik, Esslingen Am Neckar, 73730, Germany|Malteser Krankenhaus St. Franziskus-Hospital, Flensburg, 24939, Germany|Krankenhaus Nordwest, Frankfurt am Main, 60488, Germany|Asklepios Fachkliniken GmbH, Gauting, 82131, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, 07548, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, 70839, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, 69126, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, 34376, Germany|St. Vincentius Kliniken Karlsruhe, Karlsruhe, 76137, Germany|Klinikum Kassel; Hautklinik, Kassel, 34125, Germany|Katholisches Klinikum Marienhof, Koblenz Am Rhein, 56073, Germany|Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I, Lubeck, 23538, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, 68167, Germany|Johannes Wesling Klinikum Minden, Minden, 32429, Germany|LMU Klinikum der Universitat Munchen, Munchen, 80337, Germany|Universitätsklinikum Tübingen, Tuebingen, 72076, Germany|Praxis fur Haematologie und Internistische Onkologie, Velbert, 42551, Germany|Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie, Villingen-Schwenningen, 78052, Germany|Helios Klinik Wuppertal, Wuppertal, 42283, Germany|Soroka University Medical Centre, Beer Sheva, 8410101, Israel|Assaf Harofeh Medical Center, Beer Yaakov, 70300, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, 9112000, Israel|Meir Medical Center; Oncology, Kfar-Saba, 4428164, Israel|Galilee Medical Center, Nahariya, 22100, Israel|Rabin Medical Center, Petach Tiqwa, 49100, Israel|Chaim Sheba Medical Center, Ramat Gan, 5265601, Israel|Rambam Health Corporation; Oncology Institute, Rambam, 3525408, Israel|Kaplan Medical Center, Rehovot, 7610001, Israel|Tel Aviv Sourasky Medical Ctr; Oncology, Tel Aviv, 6423906, Israel|Ospedale Clinicizzato SS Annunziata, Chieti, Abruzzo, 66100, Italy|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Campania, 83100, Italy|Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica, Napoli, Campania, 80131, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, 62100, Italy|Ospedale Santa Maria Della; Misericordia Di Perugia; Farmacia Ospedaliera, Perugia, Umbria, 06129, Italy|Consorcio Hospitalario Provincial de Castellon, Castellon DE LA Plana/castello DE LA Plana, Castellon, 12002, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, 07198, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, LA Coruña, 15006, Spain|Hospital Universitario de Torrejon, Torrejon de Ardoz, Madrid, 28850, Spain|Hospital Universitario de Canarias, S. Cristobal De La Laguna, Tenerife, 38320, Spain|Hospital Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital de San Pedro de Alcantara, Caceres, 10003, Spain|Hospital Universitario Virgen de Las Nieves, Granada, 18012, Spain|Hospital General Universitario de Guadalajara, Guadalajara, 19002, Spain|Complejo Hospitalario de Jaen, Jaen, 23007, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital NisA 9 de Octubre, Valencia, 46015, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/81/NCT02367781/Prot_SAP_000.pdf"
